Abstract
LW1497 suppresses the expression of the hypoxia-inducing factor (HIF)-1α inhibiting malate dehydrogenase. Although hypoxia and HIF-1α are known to be important in cancer, LW1497 has not been therapeutically applied to cancer yet. Thus, we investigated the effect of LW1497 on the epithelial-mesenchymal transition (EMT) of lung cancer cells. A549 and H1299 lung cancer cells were induced to undergo via TGF-β1 treatment, resulting in the downregulation of E-cadherin and upregulation of N-cadherin and Vimentin concurrently with increases in the migration and invasion capacities of the cells. These effects of TGF-β1 were suppressed upon co-treatment of the cells with LW1497. An RNA-seq analysis revealed that LW1497 induced differential expression of genes related to hypoxia, RNA splicing, angiogenesis, cell migration, and metastasis in the A549 lung cancer cell lines. We confirmed the differential expression of Slug, an EMT-related transcription factor. Results from Western blotting and RT-PCR confirmed that LW1497 inhibited the expression of EMT markers and Slug. After orthotopically transplanting A549 cancer cells into mice, LW1497 was administered to examine whether the lung cancer progression was inhibited. We observed that LW1497 reduced the area of cancer. In addition, the results from immunohistochemical analyses showed that LW1497 downregulated EMT markers and Slug. In conclusion, LW1497 suppresses cancer progression through the inhibition of EMT by downregulating Slug.
Highlights
The TGF-β1-induced fluctuations in the levels of the epithelial-mesenchymal transition (EMT) markers were suppressed by 10 μM LW1497 co-treatment (Figure 1A,B)
Changes in the EMT markers were confirmed by qRT-Polymerase Chain Reaction (PCR) (Figure 1C)
The effects of LW1497 on the EMT markers were confirmed via confocal microscopy (Figure 1D)
Summary
Lung cancer is the most common cause of cancer-related deaths worldwide [1]. 85% of lung cancer cases are due to non-small cell lung cancers (NSCLC), the most common of which is adenocarcinomas [2,3]. Metastasis is the leading cause of death in cancer patients. A subtype of NSCLC, is a highly metastatic disease, with approximately 22% of patients presenting with regional lymph node metastases and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.